Clustering of adverse events. An investigation was prompted when the U.S. Food and Drug Administration received a report of an increased frequency of an adverse drug-related event after a hospital switched from the innovator company’s product to a generic product.

To address this issue, a team of investigators completed chart reviews of patients who had received the drugs in question. Table